Drug General Information (ID: DDITA6O5ZY)
Drug Name			Vorapaxar		Drug Info		Betrixaban		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiplatelet Agents/Protease-Activated Receptor-1 Antagonists				Anticoagulants/Factor Xa Inhibitors
Structure

Mechanism of Vorapaxar-Betrixaban Interaction (Severity Level: Major)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Vorapaxar				Betrixaban
Mechanism		Risk of bleeding Antiplatelet				Risk of bleeding Anticoagulant
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Vorapaxar and Betrixaban

Recommended Action
Management		Concomitant use of vorapaxar with warfarin or other anticoagulants should generally be avoided.

References
1	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.